Results from an observational study in Hungary show a high level of estimated effectiveness for five coronavirus vaccines.
The research was based on observations between January and June, with residents of Hungary receiving two doses of either Russia's Sputnik V, Moderna’s (Nasdaq: MRNA) jab Spikevax, the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) vaccine Comirnaty, China’s Sinopharm vaccine or AstraZeneca’s (LSE: AZN) Vaxzevria.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund and cheerleader for the country’s coronavirus vaccine, announced that its jab had the highest impact in preventing COVID-related mortality, at 98%, as well as 87% effectiveness against infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze